Key figures as at Decembre 31, 2016

 

Cash, cash equivalents and financial instruments*

€230.7m

* Including current and non-current

Financial debt

€5.3m


Staff

154 employees, 3/4 of whom are dedicated to R&D


Portfolio

7 programs in development:

  • 3 programs in clinical trials including one licensed to Bristol-Myers Squibb and one partnered with AstraZeneca
  • 4 proprietary preclinical programs

See FY financial results for 2016